Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review and Clinical Experience)

YuE Vinogradova1, NG Chernova2

1 IM Sechenov First Moscow State Medical University, 8 bld. 2 Trubetskaya Str., Moscow, Russian Federation, 119991

2 National Medical Hematology Research Center, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Yuliya Eikhenovna Vinogradova, MD, PhD, 8 bld. 2 Trubetskaya str., Moscow, Russian Federation, 119991; Tel.: +7(495)609-14-00, +7(916)195-68-57; е-mail: jvinogr@gmail.com

For citation: Vinogradova YuE, Chernova NG. Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review and Clinical Experience). Clinical oncohematology. 2019;12(2):179–84.

DOI: 10.21320/2500-2139-2019-12-2-179-184


Peripheral T-cell lymphomas (PTCL) are characterized by unfavorable prognosis and poorer survival in comparison with B-cell lymphomas. Probability of remission on first-line PTCL therapy is not higher than 60 % with high relapse rate. Long-term remission in PTCL relapses/progression cases typically fails to be achieved. The present article provides literature review and the authors’ own clinical experience in the management of anaplastic large-cell lymphoma, ALK-positive with primary skin and soft tissue lesions in an 65-year old female patient. After NHL-BFM-90 intensive chemotherapy the first 5,5-year complete remission was achieved in this patient. Afterwards a СНОР therapy-resistant relapse was identified. Chemotherapy-resistance of tumor was successfully overcome by adding of epigenetic drugs to cytostatic antitumor therapy. The duration of second complete remission is 3 years. Oncohematological diseases with either initial chemotherapy-resistance or the resistance acquired during antitumor therapy are most efficiently treated by various drug combinations including monoclonal antibodies, epigenetic drugs, and cytostatic therapy.

Keywords: anaplastic large-cell lymphoma, ALK-positive, skin involvements, resistance associated with relapse, epigenetic drugs.

Received: July 26, 2018

Accepted: January 15, 2019

Read in PDF 


  1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. doi: 10.1200/JCO.2008.16.4558.

  2. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol. 1990;8(7):1163–72. doi: 10.1200/JCO.1990.8.7.1163.

  3. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. 2008;111(12):5496–504. doi: 10.1182/blood-2008-01-134270.

  4. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012;83(2):293–302. doi: 10.1016/j.critrevonc.2012.02.005.

  5. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–6. doi: 10.1200/JCO.2012.44.7524.

  6. Виноградова Ю.Е., Луценко И.Н., Капланская И.Б. и др. Эффективность терапии различных вариантов анаплазированных Т-крупноклеточных лимфом. Терапевтический архив. 2008;80(7):33–7.

    [Vinogradova YuE, Lutsenko IN, Kaplanskaya IB, et al. Efficacy of therapy of different variants of anaplastic large T-cell lymphomas. Terapevticheskii arkhiv. 2008;80(7):33–7. (In Russ)]

  7. Hutchins LF, Moon J, Clark JI, et al. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer. 2007;110(10):2269–75. doi: 10.1002/cncr.23035.

  8. Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Fut Med. Chem. 2012;4(4):471–86. doi: 10.4155/fmc.12.6.

  9. Witzig TE, Reeder C, Han JJ, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126(3):328–35. doi: 10.1182/blood-2015-02-629543.

  10. Vose JM, Link BK, Grossbard ML, et al. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2005;46(11):1569–73. doi: 10.1080/10428190500217312.

  11. Vaishampayan UN, Heilbrun LK, Marsack C, et al. Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anticancer Drugs. 2007;18(10):1221–6. doi: 10.1097/CAD.0b013e3282eea391.

  12. Younes A, Bartlett N, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21. doi: 10.1056/NEJMoa1002965.

  13. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–17. doi: 10.1182/blood-2017-05-780049.

  14. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7(1):24. doi: 10.1186/1756-8722-7-24.

  15. Lamarque M, Bossard C, Contejean A, et al. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica. 2016;101(3):e103–6. doi: 10.3324/haematol.2015.135400.

  16. Fanale MA, Horwitz SM, Forero-Torres A, et al.. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137–43. doi: 0.1200/JCO.2013.54.2456.

  17. Morel A, Briere J, Lamant L, et al. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. Eur J Cancer. 2017;83:146–53. doi: 10.1016/j.ejca.2017.06.026.

  18. Виноградова Ю.Е., Потекаев Н.С., Виноградов Д.Л. Лимфомы кожи. Диагностика и лечение. М.: Практическая медицина, 175 c.

    [Vinogradova YuE, Potekaev NS, Vinogradov DL. Limfomy kozhi. Diagnostika i lechenie. (Skin lymphomas: diagnosis and treatment.) Moscow: Prakticheskaya meditsina Publ.; 2014. 175 p. (In Russ)]

  19. Hoelzer D, Gokbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002;99(12):4379–85. doi: 10.1182/blood-2002-01-0110.

  20. Паровичникова Е.Н., Клясова Г.А., Исаев В.Г. и др. Первые итоги терапии Ph-негативных острых лимфобластных лейкозов взрослых по протоколу научно-исследовательской группы гематологических центров России ОЛЛ-2009. Терапевтический архив. 2011;83(7):11–

    [Parovichnikova EN, Klyasova GA, Isaev VG, et al. Pilot results of therapy of adult Ph-negative acute lymphoblastic leukemia according to the protocol of Research Group of Russian Hematological Centers ALL-2009. Terapevticheskii arkhiv. 2011;83(7):11–7. (In Russ)]

  21. Виноградова Ю.Е., Чернова Н.Г., Капланская И.Б. и др. Отдаленные результаты лечения Т-клеточных лимфобластных лимфом. Терапевтический архив. 2012;84(8):57–60.

    [Vinogradova YuE, Chernova NG, Kaplanskaya IB, et al. Long-term results of treatment for T-cell lymphoblastic lymphomas. Terapevticheskii arkhiv. 2012;84(8):57–60. (In Russ)]

  22. Чернова Н.Г., Виноградова Ю.Е., Сидорова Ю.В. и др. Длительные режимы цитостатической терапии ангиоиммунобластной Т-клеточной лимфомы. Клиническая онкогематология. 2014;7(1):57–62.

    [Chernova NG, Vinogradova YuE, Sidorova YV, et al. Prolonged chemotherapy for angioimmunoblastic T-cell lymphoma. Klinicheskaya onkogematologiya. 2014;7(1):57–62. (In Russ)]

  23. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol. 1994;12(5):899–908. doi: 10.1200/JCO.1994.12.5.899.

  24. Виноградова Ю.Е., Зингерман Б.В. Нозологические формы и выживаемость пациентов с Т- и NK-клеточными лимфатическими опухолями, наблюдавшихся в ГНЦ в течение 10 лет. Клиническая онкогематология. 2011;4(3):201–12.

    [Vinogradova YuE, Zingerman BV. Nosological forms and survival of patients with T- and NK-cell lymphatic tumors, followed-up at HRC for 10 years. Klinicheskaya onkogematologiya. 2011;4(3):201–12. (In Russ)]

  25. Aviles A, Neri N, Nambo MJ, et al. Novel therapy in multiple myeloma. Invest New Drugs. 2005;23(5):411–5. doi: 10.1007/s10637-005-2900-6.

  26. Горенкова Л.Г., Виноградова Ю.Е., Кравченко С.К. и др. Анаплазированная Т-крупноклеточная АЛК-положительная лимфосаркома с изолированным поражением кожи и мягких тканей у пожилой больной. Гематология и трансфузиология. 2011;56(1):31–3.

    [Gorenkova LG, Vinogradova YuE, Kravchenko SK, et al. Anaplastic T-cell ALK-positive lymphoma with isolated involvement of the skin and soft tissues in an elderly female patient. Gematologiya i transfuziologiya. 2011;56(1):31–3. (In Russ)]

  27. Geller S, Canavan TN, Pulitzer M, et al. ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. Int J Dermatol. 2018;57(5):515–20. doi: 10.1111/ijd.13804.

  28. Oschlies I, Lisfeld J, Lamant L, et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 2013;98(1):50–6. doi: 10.3324/haematol.2012.065664.

  29. Сидорова Ю.В., Чернова Н.Г., Рыжикова Н.В. и др. Клональные реаранжировки и опухолевые клоны при периферической Т-клеточной лимфоме. Acta Naturae. 2015;7(3):130–40.

    [Sidorova YuV, Chernova NG, Ryzhikova NV, et al. Clonal rearrangements and malignant clones in peripheral T-cell lymphoma. Acta Naturae. 2015;7(3):130–40. (In Russ)]